Article
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) - 1 Sept 2008
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher Me, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G
Abstract excerpt
A sixth month phase II multicenter-pilot trial with a low dose of the opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The primary end points were safety and tolerability. Secondary outcomes were efficacy on spasticity, pain, fatigue, depression, and quality of life. Clinical and biochemical evaluations were serially performed. Protein...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.